Limitations of the Barcelona clinic liver cancer staging treatment strategy in hepatocellular carcinoma patients with performance status 1.
作者信息
Yu Jung Hwan, Lee Jin-Woo
机构信息
Department of Internal Medicine, Inha University Hospital and School of Medicine, Incheon, South Korea.
出版信息
Ann Transl Med. 2020 Sep;8(17):1042. doi: 10.21037/atm-20-4316.
Abstract
摘要
相似文献
1
Limitations of the Barcelona clinic liver cancer staging treatment strategy in hepatocellular carcinoma patients with performance status 1.巴塞罗那临床肝癌分期治疗策略在体能状态为1的肝细胞癌患者中的局限性。
Ann Transl Med. 2020 Sep;8(17):1042. doi: 10.21037/atm-20-4316.
2
Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system.肝细胞癌患者的转移：发生率、决定因素、预后影响以及对巴塞罗那临床肝癌系统的改善能力。
Liver Int. 2018 Oct;38(10):1803-1811. doi: 10.1111/liv.13748. Epub 2018 Apr 24.
3
Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients.巴塞罗那临床肝癌指南内外肝癌切除术后治愈机会的定义：1010 例多机构分析。
Surgery. 2019 Dec;166(6):967-974. doi: 10.1016/j.surg.2019.08.010. Epub 2019 Oct 9.
4
Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.美国癌症联合委员会第 8 版分期系统与巴塞罗那临床肝癌分类在肝细胞癌患者中的生存预测性比较。
Oncologist. 2021 Mar;26(3):e445-e453. doi: 10.1002/onco.13535. Epub 2020 Oct 3.
5
Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?重新思考巴塞罗那临床肝癌指南：中期和 Child-Pugh B 患者适合手术吗？
World J Gastroenterol. 2021 Jun 7;27(21):2784-2794. doi: 10.3748/wjg.v27.i21.2784.
6
A proposed modification for the Barcelona Clinic Liver Cancer staging system: Adding bile duct tumor thrombus status in patients with hepatocellular carcinoma.巴塞罗那临床肝癌分期系统的拟议修正：在肝细胞癌患者中加入胆管癌栓状态。
Am J Surg. 2020 Oct;220(4):965-971. doi: 10.1016/j.amjsurg.2020.04.003. Epub 2020 Apr 18.
7
Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.更积极的治疗能否改善肝细胞癌患者的预后？香港肝癌和巴塞罗那临床肝癌算法的直接比较。
Gut Liver. 2018 Jan 15;12(1):94-101. doi: 10.5009/gnl17040.
8
Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore.巴塞罗那临床肝癌分期系统和香港肝癌分期系统在新加坡肝细胞癌中的有效性。
J Hepatobiliary Pancreat Sci. 2017 Mar;24(3):143-152. doi: 10.1002/jhbp.423. Epub 2017 Feb 15.
9
Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.腹水和甲胎蛋白可改善巴塞罗那临床肝癌分期的预后性能。
World J Gastroenterol. 2015 May 14;21(18):5654-62. doi: 10.3748/wjg.v21.i18.5654.
10
A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status.巴塞罗那临床肝癌分期系统修正提案：考虑体能状态的预后意义。
Gut Liver. 2019 Sep 15;13(5):557-568. doi: 10.5009/gnl18444.
引用本文的文献
1
Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.骨密度可预测肝细胞癌合并门静脉癌栓患者的生存率。
PLoS One. 2025 Aug 22;20(8):e0330336. doi: 10.1371/journal.pone.0330336. eCollection 2025.
2
Efficacy of Αtezolizumab-Βevacizumab in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression, the type of BCLC-C and liver disease severity.根据疾病进展类型、BCLC-C 类型和肝病严重程度，阿替利珠单抗联合贝伐珠单抗在 BCLC-C 肝硬化合并肝细胞癌患者中的疗效。
J Cancer Res Clin Oncol. 2023 Sep;149(11):9253-9261. doi: 10.1007/s00432-023-04846-4. Epub 2023 May 18.
3
The Additive Value of Radiomics Features Extracted from Baseline MR Images to the Barcelona Clinic Liver Cancer (BCLC) Staging System in Predicting Transplant-Free Survival in Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Analysis.从基线磁共振成像（MRI）中提取的影像组学特征对巴塞罗那临床肝癌（BCLC）分期系统预测肝细胞癌患者无移植生存的附加价值：一项单中心回顾性分析
Diagnostics (Basel). 2023 Feb 2;13(3):552. doi: 10.3390/diagnostics13030552.
本文引用的文献
1
Identifying optimal candidates of transarterial chemoembolization (TACE) sorafenib in patients with unresectable hepatocellular carcinoma.确定不可切除肝细胞癌患者经动脉化疗栓塞术（TACE）联合索拉非尼治疗的最佳候选者。
Ann Transl Med. 2020 May;8(9):587. doi: 10.21037/atm.2020.02.123.
2
Immune checkpoint inhibitors for hepatocellular carcinoma.免疫检查点抑制剂治疗肝细胞癌。
Cancer. 2019 Oct 1;125(19):3312-3319. doi: 10.1002/cncr.32076. Epub 2019 Jul 10.
3
A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status.巴塞罗那临床肝癌分期系统修正提案：考虑体能状态的预后意义。
Gut Liver. 2019 Sep 15;13(5):557-568. doi: 10.5009/gnl18444.
4
Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.肝细胞癌：靶向治疗与免疫治疗综述
J Gastrointest Cancer. 2018 Sep;49(3):227-236. doi: 10.1007/s12029-018-0121-4.
5
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
6
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.晚期肝细胞癌患者需要个性化管理：来自临床实践的教训。
Hepatology. 2018 May;67(5):1784-1796. doi: 10.1002/hep.29668. Epub 2018 Apr 6.
7
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.伴有大血管侵犯或转移的晚期肝细胞癌的治疗方法：系统评价和荟萃分析。
Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486.
8
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.《亚太地区肝细胞癌管理临床实践指南：2017年更新版》
Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15.
9
10
Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis.肝功能状态对合并肝硬化的肝细胞癌患者的临床意义。
J Cancer. 2015 Feb 26;6(4):394-402. doi: 10.7150/jca.11212. eCollection 2015.
Zotero 插件